MetaADEDB 2.0 @ LMMD
levocetirizine
(CUSPGNDCPOVPBA-ZMBIFBSDSA-N)
Structure
SMILES
OC(=O)COCCN1CCN(CC1)[C@@H](c1ccc(cc1)Cl)c1ccccc1.Cl
Molecular Formula:
C21H26Cl2N2O3
Molecular Weight:
425.349
Log P:
3.8260
Hydrogen Bond Acceptor:
5
Hydrogen Bond Donor:
2
TPSA:
53.01
CAS Number(s):
823178-28-5
Synonym(s)
1.
levocetirizine
2.
(2-(4-((R)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride
3.
(2-(4-((R)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid
4.
UCB-28556
5.
Xusal
6.
Xyzal
7.
acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-
8.
acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride
9.
cetirizine (R)-form dihydrochloride
10.
levocetirizine dihydrochloride
11.
levocetirizine hydrochloride
12.
levocetrizine
External Link(s)
MeSHC472067
PubChem Compound67336450
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1SomnolenceFAERS: 6US FAERS
2MalaiseFAERS: 3US FAERS
3PalpitationsFAERS: 3US FAERS
4Altered state of consciousnessFAERS: 2US FAERS
5FatigueFAERS: 2US FAERS
6HeadacheFAERS: 2US FAERS
7NervousnessFAERS: 2US FAERS
8PneumoniaFAERS: 2US FAERS
9Accidental overdoseFAERS: 1US FAERS
10AnxietyFAERS: 1US FAERS
11Blood urine presentFAERS: 1US FAERS
12CheilitisFAERS: 1US FAERS
13Completed SuicideFAERS: 1US FAERS
14DeliriumFAERS: 1US FAERS
15Depressed Level of ConsciousnessFAERS: 1US FAERS
16DizzinessFAERS: 1US FAERS
17Drug administration errorFAERS: 1US FAERS
18Drug ineffectiveFAERS: 1US FAERS
19EpistaxisFAERS: 1US FAERS
20Feeling abnormalFAERS: 1US FAERS
21HypersensitivityFAERS: 1US FAERS
22Intentional product misuseFAERS: 1US FAERS
23Mental impairmentFAERS: 1US FAERS
24StomatitisFAERS: 1US FAERS
25SunburnFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.